Vivos Therapeutics, Inc. Launches Promising Treatment of Mild to Moderate Obstructive Sleep Apnea in Adults
Obstructive Sleep Apnea (“OSA”) impacts up to 1 billion people globally, including 54 million Americans Estimates suggest OSA costs the U.S. economy $165 billion annually Vivos System offers significant advantages over traditional OSA treatment approaches Over 4,300 healthcare professionals registered for Vivos’ education and training Summit in March 2020, with strong and growing interest in this disruptive new technology Vivos Therapeutics’ Vivos System is the first treatment modality for mild to moderate OSA based on the ability to remodel and enhance the function, size, and shape of the human airway, in most cases avoiding the need for lifelong interventions. The…
